At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 205 enrolled
Drug / intervention
Neovascular Age-related Macular Degenerationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients
In Brief
A Phase 4 clinical trial evaluating Neovascular Age-related Macular Degeneration for Neovacular Age-related Macular Degeneration. Completed, enrolled 205 participants across 24 sites in 7 countries.
Detailed Summary
This study assessed systemic vascular endothelial growth factor (VEGF) level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept. Free plasma VEGF-A level was measured in this study .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartApr 2014
Primary CompletionSep 2015
TodayJul 2026
First PostedNov 20, 2013
Enrollment StartApr 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.6 years ago
Interventions
Neovascular Age-related Macular Degenerationprocedure
Blood measurement